Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) Predominantly squamous cell histology Cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy Advanced disease, meeting 1 of the following staging criteria: Stage IIIB disease with malignant pleural effusion Stage IV disease Recurrent, unresectable disease Measurable or nonmeasurable disease No extrathoracic only disease No known CNS metastases by head CT scan with contrast or MRI PATIENT CHARACTERISTICS: ECOG performance status 0-1 Platelet count > 100,000/mm^3 Absolute neutrophil count > 1,500/mm^3 Bilirubin < 1.5 mg/dL Transaminases < 5 times upper limit of normal (ULN) Creatinine clearance ≥ 45 mL/min Urine protein:creatinine ratio ≤ 1.0 by spot urinalysis INR < 1.5 ULN PTT normal Not pregnant or nursing Negative pregnancy test Fertile patients use effective contraception No serious nonhealing wound, ulcer, or bone fracture No ongoing or active infection No ongoing fever No myocardial infarction within the past 6 months No stroke within the past 6 months No history of hypertension unless well-controlled (i.e., blood pressure < 150/100 mmHg on a stable regimen of antihypertensive therapy) No New York Heart Association grade III or IV congestive heart failure No serious cardiac arrhythmia requiring medication No unstable angina pectoris No peripheral vascular disease ≥ grade 2 No other clinically significant cardiovascular disease No abdominal fistula No gastrointestinal perforation No intra-abdominal abscess within the past 6 months No psychiatric illness or social situation that would preclude study compliance No other malignancy curatively treated within the past 5 years No history of thrombotic or hemorrhagic disorders No gross hemoptysis (i.e., red blood ≥ ½ teaspoon) within the past 3 months No bleeding requiring intervention or ≥ grade 2 PRIOR CONCURRENT THERAPY: Recovered from prior therapy No prior systemic chemotherapy for metastatic NSCLC More than 6 months since prior adjuvant chemotherapy for early stage (i.e., stage IB-IIIA) NSCLC More than 3 weeks since prior immunotherapy, hormonal therapy, or radiotherapy More than 28 days since prior and no concurrent major surgery More than 7 days since prior minor surgery, fine-needle aspiration, or core biopsy More than 4 weeks since prior and no concurrent participation in another experimental drug study No concurrent therapeutic anticoagulation Concurrent prophylactic anticoagulation of venous access device allowed No concurrent chronic treatment with aspirin (> 325 mg/day) or nonsteroidal anti-inflammatory drugs known to inhibit platelet function No concurrent dipyridamole, ticlopidine, clopidogrel, or cilostazol